11 results match your criteria: "Centre Hospitalier Universitaire de Bourgogne[Affiliation]"

Pulmonary Hypertension Associated With Trastuzumab-Emtansine: An Analysis of French PH Registry and WHO Pharmacovigilance Database.

Chest

November 2024

INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Assistance Puplique - Hôpitaux de Paris (AP-HP), service de pharmacie, Hôpital Bicêtre, Le Kremlin Bicêtre, France; Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France; Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France. Electronic address:

Background: Trastuzumab emtansine has been recently suspected to be associated with the development of pulmonary arterial hypertension (PAH).

Research Question: Is there an association between trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan and the development of PAH?.

Study Design And Methods: Characteristics of incident PAH cases treated with trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan were analyzed from the French PH Registry, the VIGIAPATH program, concurrently with a pharmacovigilance disproportionality analysis using the World Health Organization pharmacovigilance database using a broad definition of pulmonary hypertension (PH) and a narrow definition of PAH.

View Article and Find Full Text PDF

Anti-IL-4R versus anti-IL-5/5R after anti-IL-5/5R failure in asthma: An emulated target trial.

J Allergy Clin Immunol

October 2024

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, équipe PEPITES, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Paris, France. Electronic address:

Article Synopsis
  • Patients with severe eosinophilic asthma often switch from one biologic treatment to another when their current medication isn't effective, but it's unclear whether switching to a different class (anti-IL-4R) or another drug in the same class (anti-IL-5/5R) is better.
  • In a study using data from a large asthma cohort, researchers compared the outcomes of patients who switched to either anti-IL-4R mAb or a different anti-IL-5/5R after not responding to their initial treatment.
  • Results showed no significant difference in asthma control improvement at six months, but the anti-IL-4R group had a more notable reduction in corticosteroid use, suggesting it might
View Article and Find Full Text PDF

Asthma loss of control after switch from anti-IL-5/5R drugs to dupilumab in severe eosinophilic asthma: A case series.

J Allergy Clin Immunol Pract

July 2024

Inserm, F-CRIN, Clinical Research Initiative in Severe Asthma: a Lever for Innovation and Science, Toulouse, France; Service de Pneumologie et Centre de Référence des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; UMR 1152, Université Paris Cité, Paris, France.

View Article and Find Full Text PDF

Growth of home respiratory equipment from 2006 to 2019 and cost control by health policies.

Respir Med Res

November 2022

Service de soins de suite et réhabilitation respiratoire (Département "R3S"), Groupe Hospitalier Pitié-Salpêtrière-Charles-Foix, AP-HP, 47-83 boulevard de l'Hôpital, 75013 Paris, France; Respiratory Support, Chronic Care Group (GAVO2) of the French respiratory Society of Respiratory Disease (SPLF), France; INSERM, UMRS 1158, Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Universités, UPMC Université Paris 06, 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France.

Background: Home respiratory equipment (HRE) designed for the management of chronic respiratory failure includes oxygen therapy (O), noninvasive ventilation (NIV) and mechanical insufflation-exsufflation (MI-E). The growth of the number of patients treated by HRE, the prevalence and the associated costs in France have not been determined.

Methods: The French open access national health insurance aggregated data was used to estimate the evolution of theses parameters from 2006 to 2019.

View Article and Find Full Text PDF

Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control.

Eur Respir J

March 2022

Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adultes de Dijon, réseau OrphaLung, Filère RespiFil, Centre Hospitalier Universitaire de Bourgogne, Dijon, France.

https://bit.ly/30Ku2AV

View Article and Find Full Text PDF

Daptomycin-induced eosinophilic pneumonia: Are there any risk factors?

Infect Dis Now

October 2021

Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence Constitutif des maladies Pulmonaires rares de l'Adultes de Dijon, réseau OrphaLung, Filère RespiFil, Centre Hospitalier Universitaire de Bourgogne, 14, rue Paul-Gaffarel, 21000 Dijon, France; Université de Bourgogne Franche-Comté, Faculté de médecine, Dijon, France; NSERM U123-1, Dijon, France.

Objectives: Daptomycin is a widely used antibiotic. Rhabdomyolysis related to daptomycin is one of the adverse effects of treatment, justifying the need for regular monitoring of muscle enzymes throughout treatment. Daptomycin may also lead to eosinophilic pneumonia.

View Article and Find Full Text PDF

Purpose: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor outcome and limited therapeutic options. Imaging of IPF is limited to high-resolution computed tomography (HRCT) which is often not sufficient for a definite diagnosis and has a limited impact on therapeutic decision and patient management. Hypoxia of the lung is a significant feature of IPF but its role on disease progression remains elusive.

View Article and Find Full Text PDF

HSP47: a potential target for fibrotic diseases and implications for therapy.

Expert Opin Ther Targets

January 2021

McMaster University, Department of medicine, FIRH, 50 Charlton Avenue East, Hamilton , Ontario, Canada.

: Chronic fibrotic disorders are challenging clinical problems. The major challenge is the identification of specific targets expressed selectively in fibrotic tissues. Collagen accumulation is the hallmark fibrosis.

View Article and Find Full Text PDF

[Sclerosing pneumocytoma: A rare and benign tumor].

Rev Mal Respir

November 2020

Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence Constitutif des maladies Pulmonaires rares de l'Adulte de Dijon, réseau OrphaLung, Filère RespiFil, Centre Hospitalier Universitaire de Bourgogne, Dijon, France; Université de Bourgogne Franche-Comté, Faculté de médecine, Dijon, France; Inserm U123-1, Dijon, France. Electronic address:

Introduction: Sclerosing pneumocytoma is a benign and rare lung tumor affecting epithelial cells. In most cases, patients are asymptomatic and the diagnosis is made on an X ray or a CT scan performed for other enquiry. Sex ratio favors women.

View Article and Find Full Text PDF

Oral-facial-digital (OFD) syndromes are a subgroup of ciliopathies distinguished by the co-occurrence of hamartomas and/or multiple frenula of the oral region and digital anomalies. Several clinical forms of OFD syndromes are distinguished by their associated anomalies and/or inheritance patterns, and at least 20 genetic types of OFD syndromes have been delineated. We describe here a child with preaxial and postaxial polydactyly, lingual hamartoma, a congenital heart defect, delayed development and cerebellar peduncles displaying the molar tooth sign.

View Article and Find Full Text PDF